Design, synthesis and in vivo antitumor activity of novel 3, 4 di-substituted quinazoline derivatives

Objective: The present investigation is designed to synthesize some new isomeric series of quinazoline-4-one/4-thione derivatives, depending upon on the pharmacophoric model of in-vivo anticancer activity by modifying the structures retaining the fundamental structural features for the activity and screened for their antitumor properties. Methods: A new series of 7-chloro-3-[substituted (amino/phenyl amino)]-2-phenyl quinazolin-4 (3H)-one/thione derivatives and 1-(7-chloro-4-oxo/-2-phenylquinazoline-3 (4H-yl)) substituted urea derivatives were synthesized. The reaction scheme proceeds through 7-chloro-2-phenyl-4H-benzo [d] [1, 3] oxazin-4-one which is the intermediate one. The structures of the newly synthesized compounds were characterised from infrared (IR), H 1 nuclear magnetic resonance (NMR) and mass spectra (m/z) and elemental analysis. The in-vivo antitumor activity was evaluated by body weight analysis, mean survival time and percentage increase in life span methods in Swiss albino mice bearing Ehrilich ascites carcinoma (EAC). Result: The physico-chemical and spectroscopic data established the synthesis of quinazoline derivatives with a common pharmacophore. The synthesized compounds were evaluated for their antitumor properties. Among the newly quinazoline derivatives screened, six compounds (IIh, IIi, IIj, IIIh, IIIi, IIIj)) have shown significant antitumor activity. Conclusion: The quinazoline derivatives obtained from the present study indicates that the amino group at 3 rd position and urea/thiourea group in phenyl hydrazine ring at 3 rd position of quinzoline skeleton are essential for antitumor activity. Compounds IIh, IIi, IIj, IIIh, IIIi and IIIj were found to be biologically active which may be useful as potential resource for the discovery of anti-tumor compound having common quinazoline pharmacophore with lesser toxic effects.